AtaiBeckley Inc.

Listed Company

ATAICIK 0002081043NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$4.09M

Net Income

$-660.05M

Total Assets

$292.72M

Equity

$221.87M

Shares Out

364.75M

Op. Cash Flow

$-102.67M

Business

AtaiBeckley Inc. is a publicly listed company in Pharmaceutical Preparations, incorporated in Delaware. Common stock trades on Nasdaq under the ticker ATAI.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Total revenues	4	308,000
Research and development	53	55
Acquisition of in-process research and development	530	0
General and administrative	65	48
Total operating expenses	648	103
Loss from operations	−644	−103
Interest income	1	778,000
Interest expense	−1	−3
Change in fair value of assets and liabilities, net	−24	−49
Gain on other investments	4	1
Gain on consolidation of Beckley Psytech	7	0
Change in fair value of digital assets, net	−1	0
Foreign exchange loss, net	2	−1
Other income (expense), net	−3	6
Other income (expense), net	−16	−46
Net loss before income taxes	−660	−148
Benefit from (provision for) income taxes	−298,000	356,000
Losses from investments in equity method investees, net of tax	0	−2
Net loss	−660	−150
Net loss attributable to noncontrolling interests	−100,000	−780,000
Net loss attributable to ATAI Life Sciences N.V. stockholders	−660	−149
Net loss per share attributable to AtaiBeckley Inc. shareholders - basic	−2.91	−0.93
Net loss per share attributable to AtaiBeckley Inc. shareholders - diluted	−2.91	−0.93
Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - basic	227	160
Weighted average common stock outstanding attributable to AtaiBeckley Inc. Stockholders - diluted	227	160

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-02-28	FY 2024 2024-12-31
Cash and cash equivalents	85	—	18
Securities carried at fair value	135	—	45
Short-term restricted cash for other investments	0	—	10
Other current investments held at fair value	35	—	0
Prepaid expenses and other current assets	20	—	8
Total current assets	276	—	80
Property and equipment, net	2	—	3
Operating lease right-of-use assets, net	2	2	1
Other investments held at fair value	0	—	29
Other investments	0	—	42
Intangible assets, net	3	—	3
Goodwill	300,000	—	300,000
Digital assets	9	—	0
Other assets	1	—	850,000
Total assets	293	—	159
Accounts payable	5	—	3
Accrued liabilities	14	—	10
Current portion of lease liabilities	271,000	—	477,000
Short-term convertible promissory notes and derivative liability - related party	0	—	1
Short-term convertible promissory notes and derivative liability	0	—	2
Current portion of long-term debt	0	—	6
Deferred revenue	2	—	721,000
Other current liabilities	3	—	2
Total current liabilities	23	—	25
Contingent consideration liability - related party	104,000	—	110,000
Contingent consideration liabilities	205,000	—	212,000
Non-current portion of lease liabilities	2	—	732,000
Pre-funded warrant liabilities	44	—	0
Long-term debt, net	0	—	14
Other liabilities	754,000	—	3
Total liabilities	71	—	43
Commitments and contingencies (Note 20)	—	—	—
Preferred stock, $0.01 par value, 37,500,000 and zero shares authorized at December 31, 2025 and December 31, 2024, respectively; no shares issued or outstanding at December 31, 2025 and December 31, 2024	0	—	0
Common stock, $0.01 par value at December 31, 2025 and 0.10 ($0.10) par value as of December 31, 2024; 750,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 363,280,522 and 167,959,752 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	4	—	19
Additional paid-in capital	1,599	—	816
Accumulated other comprehensive loss	−21	—	−18
Accumulated deficit	−1,400	—	−700
Total stockholders' equity attributable to AtaiBeckley Inc. stockholders	222	—	116
Noncontrolling interests	127,000	—	257,000
Total stockholders' equity	222	—	117
Total liabilities and stockholders` equity	293	—	159

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Depreciation and amortization of long-term assets	1	473,000
Noncash lease expense	413,000	416,000
Amortization of debt discount	176,000	515,000
Stock-based compensation expense	14	25
Noncash change in the fair value of assets and liabilities, net	26	52
Acquisition of in-process research and development	530	0
Acquisition of in-process research and development	−7	0
Loss on disposal of fixed assets	692,000	0
Loss on lease termination	408,000	0
Loss on sale of investment held at fair value	0	2
Gain on dissolution of a variable interest entity	0	−1
Gain on settlement of pre-existing contract	0	−6
Impairment of intangible assets	33,000	919,000
Noncash change in the fair value of digital assets, net	1	0
Loss on extinguishment of debt	1	0
Unrealized foreign exchange (gain)	−2	1
Losses from investments in equity method investees, net of tax	0	2
Issuance costs allocated to pre-funded warrants	1	0
Noncash loss on sale of investment held at fair value	0	3
Other income, net	−182,000	−2
Prepaid expenses and other current assets	691,000	−1
Accounts payable	−2	−2
Accrued liabilities	−6	−7
Deferred revenue	766,000	721,000
Net cash used in operating activities	−103	−82
Proceeds from sale and maturities of securities carried at fair value	0	66
Proceeds from sale of other investment held at fair value	9	16
Cash received in acquisition of IntelGenx Corp.	0	359,000
Cash received in acquisition of Beckley Psytech Limited	5	0
Cash paid for securities carried at fair value	−89	0
Cash paid for investments	−10	−15
Cash paid for digital assets	−10	0
Cash paid for Psilera asset acquisition	−3	0
Cash paid for short-term convertible notes receivable and warrant - related party	0	−2
Cash paid for short-term notes receivable - related party	−10	−6
Cash paid for capitalized internal-use software development costs	0	−6,000
Cash paid for intangible asset	0	−83,000
Cash paid for property and equipment	−901,000	−6,000
Net cash provided by (used in) investing activities	−109	59
Proceeds from equity offerings, net of commissions	258	0
Proceeds from issuance of pre-funded warrants	22	0
Cash paid for common stock and pre-funded warrant issuance costs	−7	0
Proceeds from conversion of convertible notes to common shares	8	0
Proceeds from issuance of shares upon exercise of stock options	10	535,000
Proceeds from debt financing	0	5
Cash paid for debt financing costs	0	−161,000
Proceeds from other financing	148,000	0
Cash paid for debt extinguishment	−22	0
Net cash provided by financing activities	269	5
Effect of foreign exchange rate changes on cash	116,000	362,000
Net decrease in cash, cash equivalents and restricted cash	58	−18
Cash paid for interest	793,000	2
Cash paid for taxes	589,000	411,000
Right of use asset obtained in exchange for operating lease liabilities	2	0
Common stock issuance costs in accounts payable and accrued liabilities	6,000	0
Noncash exchange of convertible promissory note modification	0	4
Discharge of notes receivable	0	5
Noncash consideration for acquisition of Beckley Psytech	520	0
Noncash transaction costs for services rendered to Beckley Psytech	4	0
Noncash consideration for variable interest deconsolidation	0	115,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro